I’m a 21-year-old grad, why does the government want me to go on the dole to get a job? July 30, 2026 Oliver Dean was turned away from Job Centre because he wasn’t already on benefit. No wonder the welfare bill is ballooning Andy Burnham’s answer to youth unemployment has arrived. It begins with 14-year-olds, and the new technical pathways reach classrooms in September 2028. There is a great deal to be said for it and, as [...]
People read less: Do we still need the Booker Prize? July 30, 2026 The world and it’s reading habits have changed – but has the Booker Prize changed too? And what purpose does it fulfil, asks Eliot Wilson What is the point of literary prizes? The longlist for this year’s Booker Prize was announced on Tuesday, 13 works of long-form fiction by writers of any nationality, which must [...]
Here’s how to fix London listings July 30, 2026 The exodus from the London Stock Exchange demands practical solutions, not complaint, says Jonathan Dickson This week DCC Energy became the latest FTSE 100 group to be taken private, amid growing global competition for listings. Just last month, it emerged that as many as 20 FTSE 100 companies may move direct listings to New York. [...]
Ignore Palantir’s political opponents and look at the data: this technology helps patients July 30, 2026 It’s all very well for a country that can’t build a railway, a reservoir or a functioning hospital discharge process to congratulate itself on its scepticism, but the Health Foundation is wrong – Palantir’s NHS tool works, says Louis Mosley There is a ritual in British public life. A government programme shows signs of working. [...]
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026 July 29, 2026 Superiority data from LATA, together with OPERA findings, add to the clinical and real-world evidence base for long-acting injectable Cabenuva Six-month follow-up CLARITY data further reinforce a more favourable injection experience with long-acting cabotegravir compared with lenacapavir after a single dose; additional studies showcase high real-world adherence and a preference for Apretude among previous oral PrEP users EXTEND 4M explores a new investigational intramuscular cabotegravir formulation dosed three times a year for HIV prevention, as part of broader long-acting pipeline data
Carta Rearchitects Private Capital Operations with Plugins for Claude July 29, 2026 Firms managing billions in assets are cutting days of manual fund and portfolio work down to a single prompt — a shift now available to all Carta customers through Anthropic's official plugin directory.
Jacob Parsons Appointed Global CEO of Indicium AI July 29, 2026 Indicium AI has announced the appointment of Jacob Parsons as Global Chief Executive Officer. Jacob will lead delivery of the company’s global strategy, with a particular focus on building the business in the United States, the single biggest growth opportunity for the company as enterprises across every industry race to put frontier AI into production. [...]
Arendt Launches AVA, Its Proprietary AI-powered Prospectus Compliance Review Tool July 29, 2026 Arendt & Medernach, the leading independent Luxembourg-based law firm specialising in business law, investment funds, corporate law and tax, announced the launch of AVA (Arendt Visa Agent), a proprietary, purpose-built AI solution designed for UCITS prospectus compliance review. Developed in-house and built on Arendt’s own legal knowledge and methodology, with the technical architecture delivered in [...]
VoxNeuro Receives FDA 510(k) Clearance for Cognitive Function Neuroimaging (cfNI) Software – An Objective EEG/ERP Brain Health Assessment July 29, 2026 Company Engages Stillwater Capital to Explore Strategic M&A Opportunities Amid Growing Demand for Objective Assessments
Smurfit Westrock Reports Second Quarter 2026 Results July 29, 2026 Smurfit Westrock plc (NYSE: SW) today announced the financial results for the second quarter ended June 30, 2026. Key Points: Net Sales of $8,031 million Net Income of $88 million, with a Net Income Margin of 1.1% Adjusted EBITDA1 of $1,140 million, with an Adjusted EBITDA Margin1 of 14.2% Net Cash Provided by Operating Activities [...]